In ACTG 5095, nonadherence to efavirenz-containing regimens increased risk for virologic failure in blacks but not in whites.
Nonadherence to treatment is widely accepted as the major reason that antiretroviral regimens fail. However, the association between nonadherence and virologic failure varies, depending on both the drug class and the population being studied, and the underlying determinants of nonadherence are still the subject of much research. Several studies have suggested that blacks are less likely to adhere to antiretroviral therapy (ART) than are whites and that mental illness (in particular, depression) also influences adherence. Now, two new reports further explore the links among race, adherence, and risk for virologic failure.
The first report provides a detailed look at previous findings from ACTG 5095, a randomized trial of three PI-sparing regi…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)